CN103893197A - Application for naringin in preparation for medicine preventing and treating respiratory diseases due to PM2.5 particles - Google Patents
Application for naringin in preparation for medicine preventing and treating respiratory diseases due to PM2.5 particles Download PDFInfo
- Publication number
- CN103893197A CN103893197A CN201410131976.2A CN201410131976A CN103893197A CN 103893197 A CN103893197 A CN 103893197A CN 201410131976 A CN201410131976 A CN 201410131976A CN 103893197 A CN103893197 A CN 103893197A
- Authority
- CN
- China
- Prior art keywords
- naringin
- weeks
- group
- application
- plant extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses application for a natural plant extract and monomers thereof in preparation for a medicine or a healthcare product preventing and treating respiratory injuries due to PM2.5 particles. The extract and the monomers thereof are a naringin-containing natural plant extract and the naringin monomers thereof. The application is exact in curative effect on the symptoms of cough, phlegm, asthma, airway inflammation and the like due to PM2.5 particles, high in safety, obviously superior to the single effect of clinically common cough-relieving medicines, phlegm-dispelling medicines, antiasthmatic medicines and anti-inflammatory medicines at present, and capable of solving the disease of the compound occurrence of various respiratory injury symptoms due to the pollution of PM2.5 particles.
Description
Technical field
The invention discloses the application in the respiratory system damage disease that naringin causes at control PM2.5 atmospheric pollution granule.
Background technology
PM2.5 refers to that in atmosphere, aerodynamic size is less than or equal to the particulate matter of 2.5 microns, also referred to as entering lung particulate matter.Clinical research shows, the particulate matter of particle diameter >10 micron can be blocked in outside people's nose, although the particulate matter of particle diameter 2.5-10 micron can enter upper respiratory tract, but can be stopped by nasal cavity fine hair, or sticked by upper respiratory tract mucosa mucus, formation sputum excretes, therefore relatively little on healthy impact.And the particulate matter of particle diameter <2.5 micron is because too tiny being not easy stopped by the intrinsic barrier of these respiratory systems, therefore, after being inhaled into, these fine particles can directly enter bronchus, bronchioles until alveolar.
A large amount of epidemiological study discoveries, PM2.5 is very large on the impact of health.PM2.5 is rich in a large amount of poisonous and harmful substances, can disturb respiratory system ventilatory after entering pulmonary, causes pulmonary dysfunction, and Induced respiration system inflammation causes the disease of asthma, bronchitis and cardiovascular diseases aspect.Due to the as easy as rolling off a log long-time floating stop in atmosphere of PM2.5, diffusion length is far away, and therefore PM2.5 is also the good transmitting carrier of respiratory infectious disease correlated virus and antibacterial, very large on the impact of health and atmosphere quality.In view of PM2.5 is to health and sanitarian material impact, " ambient air quality " of the new revision of 2012 Nian Qi China included PM2.5 monitor value in air quality standard.
PM2.5 can cause multiple damage to respiratory system, comprises oxidative damage, inflammation damnification etc., and clinical main manifestations is the multiple symptoms such as cough, excessive phlegm, asthma and airway inflammation.But at present clinical conventional cough medicine, expectorant, anti-asthmatic and anti-inflammatory drug drug effect are single, be difficult to solve the situation of the compound appearance of multiple symptom that PM2.5 causes.For the prevention method of PM2.5, mainly concentrate on and improve environment at present, improve air quality or minimizing and go out, reduce and expose the negative and positive coping style methods such as infringement to the open air.Therefore, be necessary to continue development for preventing and treat medicine and the new type of health product of the respiratory system damage that PM2.5 causes.
Exocarpium Citri Grandis is immature fruit or the outer peel of rutaceae Huazhou Fructus Citri grandis (Citrus grandis " Tomentosa "), is again Citrus grandis Osbeck. Var.tomentosa Hort., because main product is gained the name in Huazhou City, Guangdong, is south of the Five Ridges genuine medicinal materials.Traditional Chinese medicine theory thinks, Exocarpium Citri Grandis bitter in the mouth is warm in nature, enters lung meridian spleen channel, has regulating the flow of QI to ease the stomach, effect of drying dampness to eliminate phlegm.Modern plants chemistry and pharmacological research show, naringin is bioactive ingredients important in Exocarpium Citri Grandis, and has high safety.Exocarpium Citri Grandis extract, naringin and the naringenin that contains naringin all has significant antitussive, relievings asthma, eliminates the phlegm and antiinflammatory action, but not yet has report naringin or the application for the respiratory system damage that prevents and treat PM2.5 and cause containing the natural plant extracts of naringin.
The structural formula of naringin:
Summary of the invention
Single for overcoming conventional cough medicine, expectorant, anti-asthmatic and anti-inflammatory drug drug effect, be difficult to solve the disease situation of the compound appearance of multiple symptom that PM2.5 causes, the plant extract that the invention discloses naringin monomer or contain naringin composition, the application in the respiratory system damage disease causing at preparation control PM2.5 atmospheric pollution granule.
Described naringin monomer or the plant extract that contains naringin composition can be mixed with compositions or further make the pharmaceutically any preparation of acceptable or health product or food.Suggestion can be made up of with adjuvant the medicinal or health product containing naringin natural plant extracts or naringin monomer and other effective ingredient and/or routine of 0.1-100wt.%.
The described plant extract containing naringin can be to derive from the various natural plants such as Exocarpium Citri Grandis, grapefruit, Citrus, Fructus Citri Limoniae, Fructus Aurantii, Fructus Aurantii Immaturus, orange, Fructus Citri grandis.
Described naringin can be also according to synthetic naringin crude product or the monomer obtaining of chemical method.
The experiment proved that, compositions is that 0.1-500mg/kg body weight/day has good efficacy to the respiratory system damage preventing and treatment PM2.5 causes amounting to naringin dosage, and preferred daily dose is about amounts to naringin dosage 1-300mg/kg body weight.
Test and confirm through pharmacological effect: described natural plant extracts or naringin monomer containing naringin, have remarkable inhibition PM2.5 and cause the effect that cough high response, airway hyperreactivity, pulmonary dysfunction, mucus hypersecretion and airway inflammation damage.Be embodied in: the described natural plant extracts containing naringin or naringin monomer can (1) significantly reduce cough and airway hyperreactivity (Penh-AUC), and improve dynamic lung compliance (Cdyn); (2) significantly suppress air flue goblet cell hyperplasia and mucus hypersecretion; (3) reduce pro-inflammatory cytokine interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-α) and leukotriene-B4(LTB4) level, suppress myeloperoxidase (MPO) (MPO enzyme) activity, improve the active and proinflammatory disease of lung tissue superoxide dismutase (SOD enzyme) medium LXA4 (LXA4) level that disappears simultaneously, thereby play the effect of two-ways regulation immunosuppressant airway inflammation.
In sum, containing plant extract or the naringin monomer of naringin, the various Respiratory symptoms and the damage that cause for PM2.5 have many target spots synergism.Obviously be better than at present clinical conventional cough medicine, expectorant, anti-asthmatic and the single drug effect of anti-inflammatory drug, with respect to existing medicine for treating respiratory diseases product, can solve the disease of the compound appearance of various respiratory system injury symptom that PM2.5 particle contamination causes.
Accompanying drawing explanation
Fig. 1 is the PAS dyeing tissue slice figure of blank group mucus hypersecretion effect that PM2.5 is caused;
Fig. 2 is the PAS dyeing tissue slice figure of model group mucus hypersecretion effect that PM2.5 is caused;
Fig. 3 is the PAS dyeing tissue slice figure of prednisone (8 weeks) group mucus hypersecretion effect that PM2.5 is caused;
Fig. 4 is the PAS dyeing tissue slice figure of naringin low dosage (8 weeks) group mucus hypersecretion effect that PM2.5 is caused;
Fig. 5 is the PAS dyeing tissue slice figure of dosage in naringin (8 weeks) group mucus hypersecretion effect that PM2.5 is caused;
Fig. 6 is the PAS dyeing tissue slice figure of naringin high dose (8 weeks) group mucus hypersecretion effect that PM2.5 is caused;
Fig. 7 is the PAS dyeing tissue slice figure of dosage in naringin (2 weeks) group mucus hypersecretion effect that PM2.5 is caused;
Fig. 8 is the PAS dyeing tissue slice figure of prednisone (2 weeks) group mucus hypersecretion effect that PM2.5 is caused;
Fig. 9 is the PAS dyeing tissue slice figure of codeine phosphate (2 weeks) group mucus hypersecretion effect that PM2.5 is caused;
Figure 10 is the PAS dyeing tissue slice figure of moguisteine (2 weeks) group mucus hypersecretion effect that PM2.5 is caused;
Figure 11 is the PAS dyeing tissue slice figure of levodropropizine (2 weeks) group mucus hypersecretion effect that PM2.5 is caused;
The specific embodiment
Below in conjunction with embodiment, the present invention is further described.
Naringin described in following examples all extracts purification and obtains from Exocarpium Citri Grandis, purity >98%.
Embodiment 1: the inhibitory action of cough, airway hyperreactivity and decline in pulmonary function that naringin causes PM2.5.
Get 132 of Hartley Cavia porcelluss, body weight 250～300g, be divided at random blank group, model group (all gavage gives normal saline), naringin low dosage (8 weeks) group, middle dosage (8 weeks) group, high dose (8 weeks) group and middle dosage (2 weeks) group are (respectively by 9.2, 18.4, 36.8, 18.4mg/kg body weight gavage gives naringin), prednisone (8 weeks) group and prednisone (2 weeks) group (all gavage gives prednisone 2.4mg/kg body weight), codeine phosphate (2 weeks) group (gavage gives codeine phosphate 4.8mg/kg body weight), moguisteine (2 weeks) group (gavage gives moguisteine 24mg/kg body weight), levodropropizine (2 weeks) group (gavage gives levodropropizine 14mg/kg body weight), every group 12, male and female half and half.
Cavia porcellus adapts to raise after 2 days, and model group and each administration group are carried out PM2.5 and exposed modeling to the open air, and press 0.5ml/100g body weight gastric infusion.Blank group is not accepted PM2.5 and is exposed modeling to the open air, and each group gives medicine or the normal saline of corresponding dosage during this time.Wherein model group and each 2 weeks administration groups all gave normal saline at 1～6 week, gave corresponding dosage medicine at 7～8 weeks.
PM2.5 exposes modeling to the open air: Cavia porcellus is put into and exposes case to the open air, expose to the open air in case and light 10 medicated cigarettes simultaneously, close and expose chamber door to the open air, make flue gas be full of casing, every day 1 sootiness 60min, 6 days/week, totally 8 weeks.Expose after testing PM2.5 concentration in case to the open air and be about 60mg/m
3, reach Chinese environmental air quality standard (GB3095-2012) 24 hourly average secondary level (75ug/m
3) 800 times.
After the 8th week last modeling 24h, Cavia porcellus is accepted 15 μ g/ml capsaicin spraying 2min(atomization rates: 0.5ml/min) to excite cough, detect and record spraying with BUXCO noinvasive animal lung function instrument and start the guinea pig cough's number of times in rear 10min.And computation time-Penh area under curve (Penh-AUC) is airway reactivity index.Lure and cough after 4h with the anesthesia of 30mg/kg pentobarbital sodium, circulation of qi promoting cannula, uses BUXCO to have wound animal lung function system measurement Cavia porcellus dynamic lung compliance (Cdyn).
The inhibitory action (mean ± SD) of cough, airway hyperreactivity and decline in pulmonary function that table 1. naringin causes PM2.5
Note: with the comparison of blank group:
#p<0.05,
##p<0.01; With model group comparison
*p<0.05,
*p<0.01.
Experimental result shows: PM2.5 exposes to the open air and can cause guinea pig cough's reactivity and airway reactivity to rise, and dynamic lung compliance declines.Naringin 18.4mg/kg administration 2 weeks, 9.2-36.8mg/kg administration all has remarkable antitussive effect for 8 weeks.2 weeks antitussive effects of middle dosage (18.4mg/kg) naringin administration compared with three kinds of antitussive positive drug all without significant difference.
Aspect airway hyperreactivity, with model group comparison, naringin 18.4mg/kg administration 2 or 8 weeks, 36.8mg/kg administration all can significantly reduce airway reactivity for 8 weeks, codeine phosphate, moguisteine and levodropropizine administration 2 weeks to airway hyperreactivity all without remarkable effect.Prednisone 2.4mg/kg administration can significantly reduce airway reactivity in 8 weeks, and administration 2 weeks is not remarkable.
Aspect pulmonary dynamic compliance, with model group comparison, naringin 18.4mg/kg administration 2 or 8 weeks, 9.2mg/kg administration 8 Zhou Junke significantly improve PM2.5 and expose the dynamic lung compliance of Cavia porcellus to the open air.Prednisone 2.4mg/kg administration can significantly improve dynamic lung compliance in 2 weeks.Moguisteine administration can significantly improve Cavia porcellus dynamic lung compliance in 2 weeks, but clinical dosage codeine phosphate and levodropropizine administration all can not significantly improve Cavia porcellus dynamic lung compliance for 2 weeks.When administration 2 weeks, naringin 18.4mg/kg group dynamic lung compliance is significantly higher than clinical dosage codeine phosphate, moguisteine and levodropropizine (P is respectively 0.042,0.038,0.022).Illustrate that naringin is significantly better than antitussive positive drug codeine phosphate, moguisteine and levodropropizine improving the effect that PM2.5 exposes to the open air aspect the dynamic lung compliance decline causing.
These results suggest that the symptoms such as cough that the present composition causes PM2.5, asthma, pulmonary dysfunction have good preventive and therapeutic action.
The effect of the mucus hypersecretion that embodiment 2 naringins cause PM2.5.
Get 132 of Hartley Cavia porcelluss, body weight 250～300g, be divided at random blank group, model group (all gavage gives normal saline), naringin low dosage (8 weeks) group, middle dosage (8 weeks) group, high dose (8 weeks) group and middle dosage (2 weeks) group are (respectively by 9.2, 18.4, 36.8, 18.4mg/kg body weight gavage gives naringin), prednisone (8 weeks) group and prednisone (2 weeks) group (all gavage gives prednisone 2.4mg/kg body weight), codeine phosphate (2 weeks) group (gavage gives codeine phosphate 4.8mg/kg body weight), moguisteine (2 weeks) group (gavage gives moguisteine 24mg/kg body weight), levodropropizine (2 weeks) group (gavage gives levodropropizine 14mg/kg body weight), every group 12, male and female half and half.
Cavia porcellus adapts to raise after 2 days, and model group and each administration group are carried out PM2.5 and exposed modeling to the open air, and press 0.5ml/100g body weight gastric infusion.Blank group is not accepted PM2.5 and is exposed modeling to the open air, and each group gives medicine or the normal saline of corresponding dosage during this time.Wherein model group and each 2 weeks administration groups all gave normal saline at 1～6 week, gave corresponding dosage medicine at 7～8 weeks.
PM2.5 exposes modeling to the open air: Cavia porcellus is put into and exposes case to the open air, expose to the open air in case and light 10 medicated cigarettes simultaneously, close and expose chamber door to the open air, make flue gas be full of casing, every day 1 sootiness 60min, 6 days/week, totally 8 weeks.Expose after testing PM2.5 concentration in case to the open air and be about 60mg/m
3, reach 800 times of Chinese environmental air quality standard (GB3095-2012) 24 hourly average secondary levels (75ug/m3).
After the 8th week last modeling 24h, put to death Cavia porcellus, Qu Yue 1cm tracheal tissue is fixed in 10% neutral formalin, choose at random the sample making PAS dyeing tissue slice of 3 animals, under light microscopic, (amplify 200 times) and check tracheal epithelium goblet cell hyperplasia and mucous secretion situation for every group.The results are shown in Figure 1 to Figure 11.
Experimental result shows: PM2.5 exposes to the open air and causes Guinea Pig Airway epithelium to occur obviously damage, and has promoted epithelial layer goblet cell hyperplasia and mucus hypersecretion.Naringin can be protected airway epithelia structure, suppress goblet cell hyperplasia in dose dependent ground, reduces mucous secretion, and 8 weeks effects of administration are better than administration 2 weeks; Prednisone group medication protective effect in 2 weeks is better than other 2 weeks medication groups; but the medication of prednisone group causes human airway epithelial cells to come off seriously for 8 weeks; in antitussive positive drug; only levodropropizine group has protective effect to airway epithelia; in the degree of pathology damage, effect is slightly worse than in naringin dosage medication 2 weeks.
Therefore the present composition causes PM2.5 air flue damage and mucus hypersecretion have significant preventive and therapeutic action.
Embodiment 3: naringin causes the impact of the proinflammatory inflammation factor of pulmonary and enzyme on PM2.5
Get 132 of Hartley Cavia porcelluss, body weight 250～300g, be divided at random blank group, model group (all gavage gives normal saline), naringin low dosage (8 weeks) group, middle dosage (8 weeks) group, high dose (8 weeks) group and middle dosage (2 weeks) group are (respectively by 9.2, 18.4, 36.8, 18.4mg/kg body weight gavage gives naringin), prednisone (8 weeks) group and prednisone (2 weeks) group (all gavage gives prednisone 2.4mg/kg body weight), codeine phosphate (2 weeks) group (gavage gives codeine phosphate 4.8mg/kg body weight), moguisteine (2 weeks) group (gavage gives moguisteine 24mg/kg body weight), levodropropizine (2 weeks) group (gavage gives levodropropizine 14mg/kg body weight), every group 12, male and female half and half.
Cavia porcellus adapts to raise after 2 days, and model group and each administration group are carried out PM2.5 and exposed modeling to the open air, and press 0.5ml/100g body weight gastric infusion.Blank group is not accepted PM2.5 and is exposed modeling to the open air, and each group gives medicine or the normal saline of corresponding dosage during this time.Wherein model group and each 2 weeks administration groups all gave normal saline at 1～6 week, gave corresponding dosage medicine at 7～8 weeks.
PM2.5 exposes modeling to the open air: Cavia porcellus is put into and exposes case to the open air, expose to the open air in case and light 10 medicated cigarettes simultaneously, close and expose chamber door to the open air, make flue gas be full of casing, every day 1 sootiness 60min, 6 days/week, totally 8 weeks.Expose after testing PM2.5 concentration in case to the open air and be about 60mg/m
3, reach Chinese environmental air quality standard (GB3095-2012) 24 hourly average secondary level (75ug/m
3) 800 times.
After the 8th week last modeling 24h, put to death Cavia porcellus, after ligation left bronchus, inject 5ml normal saline from tracheal intubation right lung is carried out to bronchoalveolar lavage, continuous 3 times, merge bronchoalveolar lavage fluid (BALF), ℃ preservation of centrifuging and taking supernatant-80 is to be measured, and lung tissue-80 ℃ preservation is to be measured.
Use BCA method to measure BALF supernatant total protein content, use ELISA method to measure proinflammatory inflammation factor TNF-α in BALF supernatant, IL-8, the content of LTB4, each cytokine content is expressed as pg/ μ g albumen.
The guinea pig lung tissue taking after thawing in right amount makes lung tissue homogenate, and centrifuging and taking supernatant is to be measured.Use BCA method to measure homogenate supernatant total protein content, use activity of myeloperoxidase detection kit to measure respectively in BALF MPO enzymatic activity in MPO enzymatic activity and lung tissue homogenate.
Table 2. naringin causes the impact (mean ± SD) of the proinflammatory inflammation factor of pulmonary on PM2.5
Note: with the comparison of blank group:
#p<0.05,
##p<0.01.With model group comparison
*p<0.05,
*p<0.01.
Table 3. naringin causes the impact (mean ± SD) of the MPO of pulmonary enzymatic activity on PM2.5
Note: with the comparison of blank group:
#p<0.05,
##p<0.01.With model group comparison
*p<0.05,
*p<0.01.
Experimental result shows: PM2.5 exposes to the open air and makes the MPO enzymatic activity of proinflammatory inflammation factor IL-8, TNF-α, LTB4 level and BALF and lung tissue in Cavia porcellus BALF significantly increase, and causes Cavia porcellus to produce significant airway inflammation.Naringin 18.4-36.8mg/kg administration 8 weeks, naringin 18.4mg/kg administration all can significantly reduce PM2.5 for 2 weeks and expose proinflammatory inflammation factor IL-8, TNF-α and the LTB4 content in Cavia porcellus BALF to the open air, reduce the MPO enzymatic activity of BALF supernatant, suppress air flue intracavity neutrophilic granulocyte inflammatory activity.But only naringin 18.4-36.8mg/kg administration can significantly reduce the MPO enzymatic activity of lung tissue homogenate for 8 weeks, reduce the neutrophil infiltration in airway tissue.
Therefore, the pneumonia that thing of the present invention causes for PM2.5 has significant treatment and preventive effect, and prophylactic use effect is better.
Embodiment 4: naringin causes the impact of pulmonary's anti-inflammatory factor and enzyme on PM2.5
Get 132 of Hartley Cavia porcelluss, body weight 250～300g, be divided at random blank group, model group (all gavage gives normal saline), naringin low dosage (8 weeks) group, middle dosage (8 weeks) group, high dose (8 weeks) group and middle dosage (2 weeks) group are (respectively by 9.2, 18.4, 36.8, 18.4mg/kg body weight gavage gives naringin), prednisone (8 weeks) group and prednisone (2 weeks) group (all gavage gives prednisone 2.4mg/kg body weight), codeine phosphate (2 weeks) group (gavage gives codeine phosphate 4.8mg/kg body weight), moguisteine (2 weeks) group (gavage gives moguisteine 24mg/kg body weight), levodropropizine (2 weeks) group (gavage gives levodropropizine 14mg/kg body weight), every group 12, male and female half and half.
Cavia porcellus adapts to raise after 2 days, and model group and each administration group are carried out PM2.5 and exposed modeling to the open air, and press 0.5ml/100g body weight gastric infusion.Blank group is not accepted PM2.5 and is exposed modeling to the open air, and each group gives medicine or the normal saline of corresponding dosage during this time.Wherein model group and each 2 weeks administration groups all gave normal saline at 1～6 week, gave corresponding dosage medicine at 7～8 weeks.
PM2.5 exposes modeling to the open air: Cavia porcellus is put into and exposes case to the open air, expose to the open air in case and light 10 medicated cigarettes simultaneously, close and expose chamber door to the open air, make flue gas be full of casing, every day 1 sootiness 60min, 6 days/week, totally 8 weeks.Expose after testing PM2.5 concentration in case to the open air and be about 60mg/m
3, reach 800 times of Chinese environmental air quality standard (GB3095-2012) 24 hourly average secondary levels (75ug/m3).
After the 8th week last modeling 24h, put to death Cavia porcellus, after ligation left bronchus, inject 5ml normal saline from tracheal intubation right lung is carried out to bronchoalveolar lavage, continuous 3 times, merge bronchoalveolar lavage fluid (BALF), ℃ preservation of centrifuging and taking supernatant-80 is to be measured, and lung tissue-80 ℃ preservation is to be measured.
Use BCA method to measure BALF supernatant total protein content, use ELISA method to measure the content (being expressed as pg/ μ g albumen) of anti-inflammatory factor LXA4 in BALF supernatant.
The guinea pig lung tissue taking after thawing in right amount makes lung tissue homogenate, and centrifuging and taking supernatant is to be measured.Use BCA method to measure homogenate supernatant total protein content, use SOD enzymatic activity detection kit to measure lung tissue homogenate SOD enzymatic activity.
Table 4. naringin causes the impact (mean ± SD) of pulmonary's anti-inflammatory factor variations on PM2.5
Note: with the comparison of blank group:
#p<0.05,
##p<0.01.With model group comparison
*p<0.05,
*p<0.01.
Experimental result shows: PM2.5 exposes to the open air and causes Cavia porcellus pulmonary anti-inflammatory factor LXA4 content significantly to decline, and has weakened the airway inflammation ability that disappears.PM2.5 exposes to the open air and also causes the SOD of guinea pig lung tissue enzymatic activity to decline simultaneously, and guinea pig lung tissue's oxidation resistance is significantly declined.Naringin 9.2-36.8mg/kg administration 8 weeks and naringin 18.4mg/kg administration 2 Zhou Junneng significantly improve the content of the short cytokine LXA4 that disappears, thereby have inflammation-inhibiting and promote the two-way antiinflammatory action disappearing.Naringin 9.2-36.8mg/kg administration 8 weeks and naringin 18.4mg/kg administration can also improve PM2.5 in 2 weeks and expose the SOD of guinea pig lung tissue enzymatic activity to the open air simultaneously, improve the ability of lung tissue antagonism PM2.5 oxidative damage.But prednisone 2.4mg/kg and clinical dosage codeine phosphate, moguisteine and levodropropizine administration 2 Zhou Junwei significantly improve anti-inflammatory factors LXA4 level and lung tissue SOD enzymatic activity.
Therefore the airway inflammation that, the present invention causes for PM2.5 has good prevention and therapeutic effect.
Claims (4)
1. naringin monomer or the plant extract that contains naringin composition, the application in the respiratory system damage disease causing at preparation control PM2.5 atmospheric pollution granule.
2. naringin monomer or the plant extract that contains naringin composition, the application in the high airway reactivity being caused by PM2.5 atmospheric pollution granule in preparation control, low pulmonary dynamic compliance, inflammation in respiratory system, asthma or cough disease.
3. application as claimed in claim 1 or 2, is characterized in that, described plant extract is the extract of Exocarpium Citri Grandis, grapefruit, Citrus, Fructus Citri Limoniae, Fructus Aurantii, Fructus Aurantii Immaturus, orange or Fructus Citri grandis.
4. a compositions for the plant extract that contains naringin monomer or contain naringin composition, is characterized in that in described compositions being 0.1-100wt.% containing the plant extract of naringin composition or the content of naringin monomer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410131976.2A CN103893197A (en) | 2014-04-02 | 2014-04-02 | Application for naringin in preparation for medicine preventing and treating respiratory diseases due to PM2.5 particles |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410131976.2A CN103893197A (en) | 2014-04-02 | 2014-04-02 | Application for naringin in preparation for medicine preventing and treating respiratory diseases due to PM2.5 particles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103893197A true CN103893197A (en) | 2014-07-02 |
Family
ID=50984985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410131976.2A Pending CN103893197A (en) | 2014-04-02 | 2014-04-02 | Application for naringin in preparation for medicine preventing and treating respiratory diseases due to PM2.5 particles |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103893197A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106728205A (en) * | 2016-12-29 | 2017-05-31 | 中山大学 | Application of the Exocarpium Citri Grandis extract in preventing and treating PM2.5 particle inducing chronic obstructive disease of lung acute attack medicines are prepared |
| CN107573393A (en) * | 2017-10-23 | 2018-01-12 | 梅州金柚康健康科技有限公司 | The preparation of hypo-glycosylated Pu Luning a kind of and its application in anti-inflammatory suppressing panting calming medicine |
| WO2020158800A1 (en) * | 2019-01-31 | 2020-08-06 | 株式会社ジャバララボラトリー | Floating particulate matter-induced inflammation suppressant, and food for suppressing floating particulate matter-induced inflammation |
| JP2020125281A (en) * | 2019-01-31 | 2020-08-20 | 株式会社ジャバラ・ラボラトリー | Floating particulate matter-induced inflammation suppressant, and food for suppressing floating particulate matter-induced inflammation |
| CN112544834A (en) * | 2020-12-02 | 2021-03-26 | 华南师范大学 | Preparation method of bitter beverage for preventing and treating chronic pharyngitis |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1430967A (en) * | 2003-01-21 | 2003-07-23 | 中山大学 | Naringin used in preparing medicine for curing acute and chronic bronchitis |
| CN1468602A (en) * | 2003-06-18 | 2004-01-21 | 中山大学 | Application of naringin in preparing medicine for supporting treatment of SARS |
| CN1676159A (en) * | 2004-08-26 | 2005-10-05 | 林励 | Total flavone of citrus grandis osbeckvar tomentosa hort peridium, and its extracting method and use |
| CN101129536A (en) * | 2006-08-21 | 2008-02-27 | 广东环球制药有限公司 | Method of separating and preparing membrane of flavone extractive of Huazhou pummelo |
| CN102992988A (en) * | 2012-12-19 | 2013-03-27 | 广州中天康顺生物医药有限公司 | Substituted phloroglucinol derivatives and application thereof |
-
2014
- 2014-04-02 CN CN201410131976.2A patent/CN103893197A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1430967A (en) * | 2003-01-21 | 2003-07-23 | 中山大学 | Naringin used in preparing medicine for curing acute and chronic bronchitis |
| CN1468602A (en) * | 2003-06-18 | 2004-01-21 | 中山大学 | Application of naringin in preparing medicine for supporting treatment of SARS |
| CN1676159A (en) * | 2004-08-26 | 2005-10-05 | 林励 | Total flavone of citrus grandis osbeckvar tomentosa hort peridium, and its extracting method and use |
| CN101129536A (en) * | 2006-08-21 | 2008-02-27 | 广东环球制药有限公司 | Method of separating and preparing membrane of flavone extractive of Huazhou pummelo |
| CN102992988A (en) * | 2012-12-19 | 2013-03-27 | 广州中天康顺生物医药有限公司 | Substituted phloroglucinol derivatives and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| YU-LONG LUO，ET AL: "Naringin attenuates enhanced cough, airway hyperresponsiveness and airway inflammation in a guinea pig model of chronic bronchitis induced by cigarette smoke", 《INTERNATIONAL IMMUNOPHARMACOLOGY》, vol. 13, 7 May 2012 (2012-05-07), pages 301 - 307 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106728205A (en) * | 2016-12-29 | 2017-05-31 | 中山大学 | Application of the Exocarpium Citri Grandis extract in preventing and treating PM2.5 particle inducing chronic obstructive disease of lung acute attack medicines are prepared |
| CN106728205B (en) * | 2016-12-29 | 2020-09-15 | 中山大学 | Application of pummelo peel extract in preparation of medicine for preventing and treating PM2.5 particle-induced chronic obstructive pulmonary disease acute attack |
| CN107573393A (en) * | 2017-10-23 | 2018-01-12 | 梅州金柚康健康科技有限公司 | The preparation of hypo-glycosylated Pu Luning a kind of and its application in anti-inflammatory suppressing panting calming medicine |
| WO2020158800A1 (en) * | 2019-01-31 | 2020-08-06 | 株式会社ジャバララボラトリー | Floating particulate matter-induced inflammation suppressant, and food for suppressing floating particulate matter-induced inflammation |
| JP2020125281A (en) * | 2019-01-31 | 2020-08-20 | 株式会社ジャバラ・ラボラトリー | Floating particulate matter-induced inflammation suppressant, and food for suppressing floating particulate matter-induced inflammation |
| CN112544834A (en) * | 2020-12-02 | 2021-03-26 | 华南师范大学 | Preparation method of bitter beverage for preventing and treating chronic pharyngitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101480595B1 (en) | A MEDICINAL composition for the treatment of bronchitis and preparation thereof | |
| CN103893197A (en) | Application for naringin in preparation for medicine preventing and treating respiratory diseases due to PM2.5 particles | |
| CN103169891B (en) | Novel vitamin C yinqiao tablet | |
| MX2010013567A (en) | Antiallergic marine biopolymers. | |
| CN106421039A (en) | Traditional Chinese medicine composition for preventing and treating haze-caused diseases, preparation method thereof and mask containing traditional Chinese medicine | |
| Farokhi et al. | Histophatologic changes of lung in asthmatic male rats treated with hydro-alcoholic extract of Plantago major and theophylline | |
| Du et al. | Gastroprotective effect of eupatilin, a polymethoxyflavone from Artemisia argyi H. Lév. & Vaniot, in ethanol-induced gastric mucosal injury via NF-κB signaling pathway | |
| CN103316086B (en) | Tibetan medicine for treating influenza and preparation method thereof | |
| US20100316677A1 (en) | Use of bamboo leaf total flavones in the preparation of medicine and health food for prevention and treatment of prostatic diseases | |
| CN112294911A (en) | Traditional Chinese medicine composition for treating cough with lung heat | |
| CN103494927A (en) | Traditional Chinese medicine composition for treating chicken respiratory disease and preparation method thereof | |
| CN105168500A (en) | Pharmaceutical composition used for curing infantile dental ulcer and preparation method for pharmaceutical composition | |
| CN105456234A (en) | Novel propellant asarone inhalation aerosol and preparation method thereof | |
| CN104274750B (en) | A kind of Chinese medicine composition for treating acute bronchitis, the infection of the upper respiratory tract | |
| CN104189081B (en) | It is a kind of to be used to treat Chinese medicine composition of allergic rhinitis and preparation method thereof | |
| WO2015135372A1 (en) | Application of isoforskolin in preventing and treating chronic obstructive pulmonary disease | |
| WO2015131655A1 (en) | Use of fsk in preventing and treating chronic obstructive pulmonary disease | |
| CN102526236A (en) | Pharmaceutical formulation for treating influenza and preparation method thereof | |
| Yen et al. | A kampo medicine, Yin‐Chiao‐san, Prevents bleomycin‐induced pulmonary injury in rats | |
| CN104435068B (en) | A kind of Cortex Eucommiae compositions and preparation thereof with antiobesity action | |
| KR102202122B1 (en) | Composition for anti-tussive activity or discharge of phlegm activity comprising extract of Atractylodes Rhizome White and Schizandra Fruit | |
| KR20230149129A (en) | Compositions for improving or treating asthma | |
| CN108888715A (en) | A kind of composition reducing haze particulate matter sucking associated diseases | |
| EP4051300A1 (en) | Composition for the prevention and treatment of diseases of the respiratory system | |
| TW202007406A (en) | Medicament for the treatment of cholecystitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140702 |
|
| RJ01 | Rejection of invention patent application after publication |